{'52WeekChange': -0.3423168,
 'SandP52WeekChange': None,
 'address1': '3013 Science Park Road',
 'address2': 'Suite 200',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 15.5,
 'askSize': 1800,
 'averageDailyVolume10Day': 686687,
 'averageVolume': 735030,
 'averageVolume10days': 686687,
 'beta': None,
 'beta3Year': None,
 'bid': 12.42,
 'bidSize': 900,
 'bookValue': 4.935,
 'category': None,
 'circulatingSupply': None,
 'city': 'San Diego',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 13.85,
 'dayLow': 13.44,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -2.67,
 'enterpriseToRevenue': None,
 'enterpriseValue': 535525824,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 12.981143,
 'fiftyTwoWeekHigh': 27.15,
 'fiftyTwoWeekLow': 7.52,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 39180269,
 'forwardEps': -3.35,
 'forwardPE': -4.0507464,
 'fromCurrency': None,
 'fullTimeEmployees': 171,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.21673,
 'heldPercentInstitutions': 0.74359,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/gossamerbio.com',
 'longBusinessSummary': 'Gossamer Bio, Inc., a clinical-stage '
                        'biopharmaceutical company, focuses on discovering, '
                        'acquiring, developing, and commercializing '
                        'therapeutics in the disease areas of immunology, '
                        'inflammation, and oncology in the United States. It '
                        'is developing GB001, an oral antagonist of '
                        'prostaglandin D2 receptor 2, which is in Phase IIb '
                        'clinical trial for the treatment of '
                        'moderate-to-severe eosinophilic asthma; in Phase II '
                        'clinical trial to treat patients with chronic '
                        'rhinosinusitis both with and without nasal polyps; '
                        'and in translational Phase 2 clinical trial in '
                        'patients with chronic spontaneous urticarial. The '
                        'company is also developing GB002, an orally inhaled, '
                        'small molecule, selective platelet-derived growth '
                        'factor receptor kinase inhibitor in Phase Ib clinical '
                        'trial for the treatment of pulmonary arterial '
                        'hypertension; GB004, a novel, gut-targeted, oral '
                        'small molecule in Phase Ib clinical trial for the '
                        'treatment of inflammatory bowel disease, including '
                        "ulcerative colitis and Crohn's disease; and GB1275, "
                        'an oral, small molecule, CD11b modulator in Phase 1/2 '
                        'clinical trial for the treatment of selected solid '
                        'tumor types. It has license agreements with '
                        'Pulmokine, Inc. to develop and commercialize GB002 '
                        'and certain backup compounds; and Aerpio '
                        'Pharmaceuticals, Inc. to develop and commercialize '
                        'GB004 and related compounds. The company was formerly '
                        'known as FSG, Bio, Inc. and changed its name to '
                        'Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was '
                        'founded in 2015 and is headquartered in San Diego, '
                        'California.',
 'longName': 'Gossamer Bio, Inc.',
 'market': 'us_market',
 'marketCap': 1028502848,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_548541911',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -201770000,
 'nextFiscalYearEnd': 1640908800,
 'open': 13.8,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -0.13,
 'phone': '858 684 1300',
 'previousClose': 13.91,
 'priceHint': 2,
 'priceToBook': 2.7497466,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 13.85,
 'regularMarketDayLow': 13.44,
 'regularMarketOpen': 13.8,
 'regularMarketPreviousClose': 13.91,
 'regularMarketPrice': 13.8,
 'regularMarketVolume': 291815,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 75792400,
 'sharesPercentSharesOut': 0.0765,
 'sharesShort': 5801815,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 5850416,
 'shortName': 'Gossamer Bio, Inc.',
 'shortPercentOfFloat': 0.097399995,
 'shortRatio': 8.49,
 'startDate': None,
 'state': 'CA',
 'strikePrice': None,
 'symbol': 'GOSS',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -3.3,
 'twoHundredDayAverage': 12.843993,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': 'b23a77d9-f4eb-3e8f-858d-367c07bb4901',
 'volume': 291815,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.gossamerbio.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '92121'}